Shares of Evoke plc (LON:EVOK – Get Free Report) were down 10% during trading on Thursday . The stock traded as low as GBX 50.20 ($0.65) and last traded at GBX 51.73 ($0.67). Approximately 65,066,164 shares changed hands during mid-day trading, an increase of 1,994% from the average daily volume of 3,107,171 shares. The stock had previously closed at GBX 57.45 ($0.74).
Analyst Upgrades and Downgrades
EVOK has been the topic of several analyst reports. Berenberg Bank reduced their price objective on Evoke from GBX 130 ($1.68) to GBX 90 ($1.16) and set a “buy” rating on the stock in a research note on Wednesday, December 4th. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 140 ($1.81) price target on shares of Evoke in a research report on Monday, December 16th.
View Our Latest Research Report on EVOK
Evoke Stock Performance
Evoke (LON:EVOK – Get Free Report) last issued its quarterly earnings data on Wednesday, March 26th. The company reported GBX (6.40) (($0.08)) earnings per share for the quarter. Evoke had a negative return on equity of 517.98% and a negative net margin of 8.50%. Research analysts anticipate that Evoke plc will post 12.7648305 earnings per share for the current year.
Insiders Place Their Bets
In other news, insider Andrea Gisle Joosen purchased 14,572 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The stock was purchased at an average cost of GBX 70 ($0.91) per share, with a total value of £10,200.40 ($13,202.69). Corporate insiders own 27.00% of the company’s stock.
About Evoke
Read More
- Five stocks we like better than Evoke
- Airline Stocks – Top Airline Stocks to Buy Now
- MarketBeat Week in Review – 03/24 – 03/28
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Evoke Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke and related companies with MarketBeat.com's FREE daily email newsletter.